Acibadem Kayseri Hospital, Medical Oncology, Kayseri, Turkey.
J BUON. 2020 Mar-Apr;25(2):939-944.
Whether primary tumor resection (PTR) should be performed in patients with asymptomatic colorectal cancer (CRC) and unresectable synchronous metastasis is controversial. The purpose of this study was to investigate the prognostic impact of initial primary tumor resection in patients with synchronous unresectable metastatic CRC.
The patients with unresectable synchronous metastatic CRC who had undergone primary tumor resection and then received chemotherapy were compared with the patients who received only palliative systemic chemotherapy.
Survival analysis showed that median overall survival (OS) for all patients was 22.37 months. Primary tumor resection was associated with a significant survival benefit on unadjusted analysis (median survival 29.56 months vs. 14.25 months; p<0.001). Two-year, 3-year and 5-year survival rates were 57%, 35%, 19% for the PTR group and 30%, 16%, 8% for the non-PTR group and all results were statistically significant and favored surgery.
Our study suggests that primary tumor resection improves the survival of patients with metastatic CRC and unresectable synchronous metastasis.
对于无症状结直肠癌（CRC）和不可切除的同时性转移患者，是否应进行原发肿瘤切除术（PTR）存在争议。本研究旨在探讨初始原发肿瘤切除术对同时性不可切除转移性 CRC 患者的预后影响。
将接受 PTR 然后接受化疗的不可切除的同时性转移性 CRC 患者与仅接受姑息性全身化疗的患者进行比较。
生存分析显示，所有患者的中位总生存期（OS）为 22.37 个月。原发肿瘤切除术在未调整分析中与显著的生存获益相关（中位生存时间 29.56 个月比 14.25 个月；p<0.001）。PTR 组的 2 年、3 年和 5 年生存率分别为 57%、35%、19%，而非 PTR 组分别为 30%、16%、8%，所有结果均具有统计学意义且有利于手术。
我们的研究表明，原发肿瘤切除术可改善不可切除的同时性转移性 CRC 患者的生存。
